File photo for reference only

Thailand’s FDA aims to reclassify GLP-1 slimming pens as a special controlled drug, mandating prescriptions for purchase. This move addresses misuse driven by social media promotion and aims to prevent health risks.

GLP-1 receptor agonists are currently approved in Thailand for treating type 2 diabetes and obesity-related weight reduction, not for cosmetic weight loss. The FDA, led by Supatra Boonserm, has found misuse of these meds is leading to severe side effects, including rapid weight gain upon ending use, and risks like kidney failure or depression, especially in those with existing health conditions.

The proposed reclassification would limit sales to licensed pharmacies and require a doctor's prescription for purchase. These measures aim to curb online advertising and illegal sales, as legal action alone hasn’t eradicated misuse. Pharmacists would have to maintain sales records for tracking distribution effectively.

Supatra stresses that sustainable weight loss should focus on lifestyle changes, not injections advertised as miraculous solutions. The enhanced regulation seeks to protect public health and guide individuals towards safer, long-term health strategies, reported The Nation.

Key Takeaways

• GLP-1 slimming pens face strict sales regulations in Thailand.

• Misuse has led to significant health risks amid widespread online promotion.

• Prescription-only sales aim to prevent improper use and improve safety.

Related stories:

FDA Shuts Down Factory Making Banned Memory Tonic

Thai FDA Warns Against Contaminated Herbal Balm

  

Adapted by ASEAN Now from The Nation 2026-01-07

 

 

And meanwhile in the rest of the world: it's coming out in pill form. So what if people want to use it for weight loss? their body - their choice.